Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials.
about
Maraviroc: a review of its use in HIV infection and beyondInteraction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 PolymorphismCYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.In vitro activity of antiretroviral drugs against Plasmodium falciparumBiotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolismLess Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women.Effects of etravirine on the pharmacokinetics of the integrase inhibitor S/GSK1265744.Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management.Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs.Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine.The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects.Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information.Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
P2860
Q26778504-855B7EEC-D4A1-4039-A7D9-3709C3AE0258Q28552997-DDA8B4A8-4A3D-439B-A6CC-14C4C49FE46EQ34360012-6B38F57D-63C5-4E10-B8B4-B99245B33BF6Q34400849-925FD8BF-06ED-4C9F-B964-47382E8AD565Q35363679-9B49786E-A19D-4911-B1FB-0A085A76890AQ35846917-D692C8E5-2BEE-4BCA-87CA-69271D386232Q36030485-C219C2DD-FE51-49DB-9AB6-FB42A7B7A018Q36187641-11794076-D569-47D1-8F7C-D6BFBD815E0FQ36505272-71652A95-9842-443E-B1B4-601D0AD55333Q36868170-CD695BC4-916F-4237-9EBC-5163A80D0863Q37335653-B5B3F978-9428-48D4-8960-80CB208F2D19Q37378110-81B03E1E-4501-4177-BAFC-02C7DA9B5E18Q38222092-E3001AD2-5487-41DC-A906-1A449202097AQ39080596-2996374B-DEC3-45CD-91B2-17D19CD01C24Q39353830-9F8EA423-80E0-4C9E-9612-CA3F09DFF2E5Q44394691-A078F42E-458E-43B2-8471-174F91E463B6Q44938963-B7177891-107E-4CEA-B3F7-53619EBC8924Q50668713-41985B3D-2E9F-4402-B0E5-4836900057B0Q50749129-422BD117-99BE-4EBE-9DFB-B8B46D4D347D
P2860
Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Pharmacokinetic interactions o ...... f two drug interaction trials.
@ast
Pharmacokinetic interactions o ...... f two drug interaction trials.
@en
Pharmacokinetic interactions o ...... f two drug interaction trials.
@nl
type
label
Pharmacokinetic interactions o ...... f two drug interaction trials.
@ast
Pharmacokinetic interactions o ...... f two drug interaction trials.
@en
Pharmacokinetic interactions o ...... f two drug interaction trials.
@nl
prefLabel
Pharmacokinetic interactions o ...... f two drug interaction trials.
@ast
Pharmacokinetic interactions o ...... f two drug interaction trials.
@en
Pharmacokinetic interactions o ...... f two drug interaction trials.
@nl
P2093
P2860
P356
P1476
Pharmacokinetic interactions o ...... of two drug interaction trials
@en
P2093
Caroline Ridgway
Julia Hamlin
Monika Schöller-Gyüre
Noella Ndongo
Rebecca Mack
Richard M W Hoetelmans
Samantha Abel
Sarah Tweedy
Thomas N Kakuda
Vanitha Sekar
P2860
P304
P356
10.1128/AAC.01046-10
P407
P50
P577
2011-03-07T00:00:00Z